Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 17/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515284 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057124 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL10819300 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL18057125 | 1.00 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL15149390 | 0.92 | TLR2 (0.53) | TLR2LPAR1LPAR3 | |
| SCHEMBL102391 | 0.91 | TLR2 (0.56) | TLR2LPAR1LPAR3 | |
| SCHEMBL14950501 | 0.91 | TLR2 (0.58) | TLR2LPAR1LPAR3 | |
| SCHEMBL14924385 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 | |
| SCHEMBL16475661 | 0.90 | TLR2 (0.46) | TLR2 | |
| SCHEMBL15071438 | 0.90 | TLR2 (0.57) | TLR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226132-A1 | RNA COMPOSITIONS COMPRISING A BUFFER SUBSTANCE AND METHODS FOR PREPARING, STORING AND USING THE SAME | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2024-07-11 | — | — | US | disclosed |
| US-20240226132-A1 | RNA COMPOSITIONS COMPRISING A BUFFER SUBSTANCE AND METHODS FOR PREPARING, STORING AND USING THE SAME | BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) | 2024-07-11 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| WO-2024027910-A1 | RNA FOR PREVENTING OR TREATING TUBERCULOSIS | BioNTech SE (DE) | 2024-02-08 | — | — | WO | disclosed |
| US-20230372245-A1 | LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230372245-A1 | LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110071208-A1 | LIPID ENCAPSULATED DICER-SUBSTRATE INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-03-24 | — | — | US | disclosed |
| US-7803397-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-28 | — | — | US | disclosed |
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104629-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | TLR2 390/4885LPAR1 153/4885LPAR3 88/4885 |
| US-20110076335-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | TLR2 2280/4885LPAR1 38/4885LPAR3 69/4885 |
| US-20100063135-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | LIPA, LIPG, LIPC | TLR2 428/4885LPAR1 154/4885LPAR3 169/4885 |
| US-20100076055-A1 | Cationic Lipids and Uses Thereof | LIPA, SGMS2, SGMS1 | TLR2 390/4885LPAR1 153/4885LPAR3 88/4885 |
| US-20230372245-A1 | LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | NPC1L1, SARNP, LIPA | TLR2 2684/4885LPAR1 20/4885LPAR3 32/4885 |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | LDLR, SNRPE, SARNP | TLR2 1919/4885LPAR1 91/4885LPAR3 84/4885 |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | TLR2 390/4885LPAR1 153/4885LPAR3 88/4885 |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | TLR2 390/4885LPAR1 153/4885LPAR3 88/4885 |
| US-20240226132-A1 | RNA COMPOSITIONS COMPRISING A BUFFER SUBSTANCE AND METHODS FOR PREPARING, STORING AND USING THE SAME | SNRPB2, NSUN2, RNMT | TLR2 4726/4885LPAR1 1178/4885LPAR3 1230/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | TLR2 2296/4885LPAR1 25/4885LPAR3 47/4885 |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, CRYAA, SARNP | TLR2 2772/4885LPAR1 2919/4885LPAR3 2404/4885 |
| US-20110071208-A1 | LIPID ENCAPSULATED DICER-SUBSTRATE INTERFERING RNA | AGO2, RNASE1, MTREX | TLR2 3510/4885LPAR1 551/4885LPAR3 652/4885 |
| US-20100055169-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | TLR2 390/4885LPAR1 153/4885LPAR3 88/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | TLR2 2296/4885LPAR1 25/4885LPAR3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.